| Funding Opportunity Announcement Module (FOAM) |
Resource Development |
ACF, ACL, AHRQ, CDC, CMS, FDA |
CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/OER |
The Funding Opportunity Announcement Module (FOAM) allows National Institutes of Health (NIH) Institutes and Centers and Department of Health and Human Services (HHS) Operating Divisions to develop content for and perform the needed approvals to publish funding opportunity announcements. The system has a flexible configuration to meet all of the needs for HHS Operating Divisions. In addition FOAM serves as a Federal Shared Service in collaboration with Grant Solutions supporting other agencies including Department of the Interior, Department of Housing and Urban Development, and Department of Homeland Security. FOAM achieves economies of scale by preventing the need for individual agencies to develop duplicate systems at a cost much greater than that of developing a unified system. |
| FY 22 Ending the HIV Epidemic in the US Funding Opportunity Announcement |
Research Initiative |
CDC, HRSA |
NIAID, NIDA, NIMH |
Three NIH EHE RFAs supports locally defined and culturally sensitive research projects that address the four key pillars of the EHE initiative (Diagnose, Treat, Prevent, and Respond). Specifically the NIH supports investigators in one of the 57 priority jurisdictions to work with implementing partners to develop and test locally defined and culturally sensitive solutions that align with jurisdictional EHE plans. CDC and HRSA provided key support in the development of the research topics. |
| Genetic Epidemiology of Diabetes and Obesity |
Research Initiative |
IHS |
NIDDK |
Genetic Epidemiology of Diabetes and Obesity |
| Genetic Epidemiology of Diabetic Complications |
Research Initiative |
IHS |
NIDDK |
Genetic Epidemiology of Diabetic Complications |
| Genetic Studies in the National Birth Defects Prevention Study (NBDPS) |
Research Initiative |
CDC |
NHGRI |
This study is a collaboration between The Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI) to carry out DNA sequencing and genotyping on samples collected as part of the National Birth Defects Prevention Study. |
| Genital Herpes Workshop |
Committee, Work group, Advisory group, or Task Force |
CDC |
NIAID |
This workshop was co-sponsored by NIAID and CDC to review the status of research, product development, and education on genital herpes. |
| Genitourinary Cancers Steering Committee (GUSC) Clinical Trials Planning Meeting on ‘Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer’ |
Meeting/ Workshop |
FDA |
NCI |
The purpose of this meeting was to accelerate further advances in clinical trials for patients with high-risk non-muscle invasive bladder cancer (NMIBC). The meeting focused on the evaluation of strategies incorporating intravesical therapy, systemic therapy, trimodal therapy (incorporating radiation therapy), and combination therapies toward a goal of improving bladder preservation rates and survival outcomes for patients with high risk including BCG-unresponsive NMIBC. |
| Genome in a Bottle Consortium |
Resource Development |
CDC, FDA |
NCI, NHGRI, NLM |
The Genome in a Bottle (GIAB) Consortium, hosted by the National Institute of Standards and Technology, is a public-private-academic consortium to develop the technical infrastructure (reference standards, reference methods, and reference data) to enable translation of whole human genome sequencing to clinical practice and innovations in technologies. The priority of GIAB is authoritative characterization of human genomes for use in benchmarking, including analytical validation and technology development, optimization, and demonstration. NLM/NCBI provides data portal (Data Coordination Center) and data management and contributes data analysis to GIAB. https://www.nist.gov/programs-projects/genome-bottle ; https://ftp.ncbi.nlm.nih.gov/ReferenceSamples/giab/ |
| Genomic and genetic determinants of the susceptibility to non alcoholic fatty liver disease (NAFLD) and NAFLD-related liver cancer |
Research Initiative |
FDA |
NCI |
The Food and Drug Administration (FDA)'s the National Center for Toxicological Research, and the National Cancer Institute (NCI)'s Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that determine susceptibility to the development of hepatocellular carcinoma and to examine epigenetic alterations which may be used as markers of susceptibility to disease development, and whether correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies. |
| Genomic epidemiology of norovirus GII.4 globally |
Research Initiative |
FDA |
FIC |
Collaboration with Dr. Gabriel Parra's team at FDA. His group has compiled a global genomic dataset of thousands of norovirus GII.4 genomic sequences spanning 37 years of sampling. Dr. Nidia Trovao's team at the NIH/FIC will employ molecular epidemiology concepts and phylodynamic modeling to shed light on the viral evolutionary history and transmission dynamics. We will also gain insight into the viral diversity circulating across countries/regions, how the viral effective population size changes over time, and identify source-to-sink patterns in norovirus GII.4 spread. This will be important to inform control strategies and the development of therapeutics and vaccines. |